美罗培南联合莫西沙星治疗慢性阻塞性肺疾病合并重症肺炎的疗效及对血清炎症因子水平的影响  

Efficacy of meropenem combined with moxifloxacin in the treatment of chronic obstructive pulmonary disease combined with severe pneumonia and its effect on serum inflammatory factors levels

作　　者：王娜[1] 陈宇强[2] 张琳[1] 翟莉 WANG Na;CHEN Yuqiang;ZHANG Lin;ZHAI Li(Department of Internal Three,Beijing Municipal Armed Police Corps Hospital,Beijing,100027,China;Department of Medical Service,Beijing Municipal Armed Police Corps Hospital,Beijing,100027,China)

机构地区：[1]武警北京总队医院内三科,北京100027 [2]武警北京总队医院卫勤处,北京100027

出　　处：《当代医学》2024年第5期23-27,共5页Contemporary Medicine

摘　　要：目的探讨美罗培南联合莫西沙星治疗慢性阻塞性肺疾病(COPD)合并重症肺炎的疗效及对血清炎症因子水平的影响。方法选取2017年10月至2019年12月于武警北京市总队医院治疗的90例COPD合并重症肺炎患者作为研究对象,按照自愿原则分为A组与B组,每组45例。A组给予美罗培南联合莫西沙星治疗,B组给予莫西沙星治疗。比较两组最大呼气中段量(MMF)、最大通气量(MVV)和第1秒用力呼气容积占预计值百分比(FEV1%)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、转化生长因子-β_(1)(TGF-β_(1))、降钙素原(PCT)水平及临床疗效、不良反应发生情况。结果治疗后,两组MMF、MVV均大于治疗前,FEV1%均高于治疗前,且A组MMF、MVV均大于B组,FEV_(1)%高于B组,差异有统计学意义(P<0.05)。治疗后,两组血清IL-8、TNF-α、TGF-β_(1)及PCT水平均低于治疗前,且A组低于B组,差异有统计学意义(P<0.05)。A组治疗总有效率为95.56%,高于B组的82.22%,差异有统计学意义(P<0.05)。A组并发症发生率为8.89%,低于B组的24.44%,差异有统计学意义(P<0.05)。结论美罗培南联合莫西沙星治疗COPD合并重症肺炎临床疗效显著,可显著降低患者炎症因子水平,改善肺功能,降低不良反应发生率。Objective To investigate the efficacy of meropenem combined with moxifloxacin in the treatment of chronic obstructive pulmonary disease(COPD)combined with severe pneumonia and its effect on serum inflammatory factors levels.Methods A total of 90 COPD patients with severe pneumonia who were treated in Beijing Municipal Armed Police Corps Hospital from October 2017 to December 2019 were selected as the study subjects,they were divided into the group A and the group B according to the principle of voluntariness,with 45 cases in each group.Group A was treated with meropenem and moxifloxacin,group B was treated with moxifloxacin.The maximum mid expiratory volume(MMF),maximum ventilation volume(MVV),percentage of forced expiratory volume in one second percent predicted(FEV1%),interleukin-8(IL-8),and tumor necrosis factor-α(TNF-α),transforming growth factor-β_(1)(TGF-β_(1)),procalcitonin(PCT)levels,clinical efficacy,and adverse reactions were compared between the two groups.Results After treatment,the MMF,MVV of the two groups were more than before treatment,FEV1%were higher than before treatment,and the MMF,MVV in the group A were more than those in the group B,FEV_(1)%was higher than that in the group B,the differences were statistically significant(P<0.05).After treatment,the levels of serum IL-8,TNF-α,TGF-β_(1) and PCT of the two groups were lower than before treatment,and the group A was lower than the group B,the differences were statistically significant(P<0.05).The total effective rate of treatment in the group A was 95.56%,which was higher than 82.22%in the group B,and the difference was statistically significant(P<0.05).The incidence of complications in the group A was 8.89%,which was lower than 24.44%in the group B,and the difference was statistically significant(P<0.05).Conclusion The meropenem combined with moxifloxacin has good clinical efficacy in the treatment of COPD complicated with severe pneumonia,and can significantly reduce the level of inflammatory factors,improve lung function and reduce th

关 键 词：美罗培南联合莫西沙星 慢性阻塞性肺疾病 重症肺炎 白细胞介素-8 肿瘤坏死因子-α 转化生长因子-β_(1) 

分 类 号：R563.1[医药卫生—呼吸系统]